Erica Kratz

Erica leads Regulatory Affairs and Clinical Quality Assurance at Denali. Erica’s team is responsible for leveraging Denali data to drive regulatory strategies for its novel therapies and ensuring Denali’s commitment to the highest Quality standards.

Prior to joining Denali, Erica held positions of increasing responsibility in Regulatory Affairs during 10 years at Genentech. Erica led the global regulatory strategy and execution for multiple small molecule and biologic oncology drug candidate programs ranging from IND to postmarketing, including leading the US and Canada marketing application filings for approval of Herceptin for gastric cancer and leading global Health Authority interactions in breast cancer and mesothelioma.

Erica earned her BS at the University of Arizona, and her Ph.D. at the University of California, Berkeley, in Molecular and Cell Biology.